Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer

Size: px
Start display at page:

Download "Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer"

Transcription

1 Original Articles Jpn J Clin Oncol 2012;42(6) doi: /jjco/hys046 Advance Access Publication 3 April 2012 Clinical Features and Survival Analysis of T1mic, a, bn0m0 Breast Cancer Junnan Li, Xiaodong Liu and Zhongsheng Tong * Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China *For reprints and all correspondence: Zhongsheng Tong, Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin , China. tonghang@medmail.com.cn Received September 27, 2011; accepted March 8, 2012 Objective: To analyze the clinicopathological features and prognosis of T1mic, a, bn0m0 breast cancer. Methods: The clinical data and survival status of 4487 cases of operable breast cancer treated in our hospital from 2002 to 2005 were collected, including 372 cases with T1mic, a, bn0m0 breast cancers. These patients were divided into four subtypes: Luminal A, Luminal B, triple-negative and human epidermal growth factor receptor 2-positive. Disease-free survival and risk factors for recurrence were identified. Results: We identified 372 eligible patients. The median follow-up was 78 months (range: months). Univariate analysis showed age, adjuvant endocrine therapy, hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. Multivariate analysis showed that hormonal receptor and human epidermal growth factor receptor 2 were prognostic factors. In the hormonal receptor-positive group, human epidermal growth factor receptor 2-positive patients (Luminal B) had a four times higher recurrence risk than human epidermal growth factor receptor 2 negative (Luminal A) patients. However, there was no statistically significant difference between hormonal receptor-negative groups (triple-negative and human epidermal growth factor receptor 2-positive). Conclusions: Hormonal receptor and human epidermal growth factor receptor 2 were independent factors of 5-year disease-free survival for patients with T1mic, a, bn0m0 breast cancer. The Luminal B group had a worse prognosis than the Luminal A group, but there was no statistically significant difference between triple-negative and human epidermal growth factor receptor 2-positive groups. Key words: breast neoplasms T1mic, a, bn0m0 prognosis INTRODUCTION Breast cancer is a major cause of morbidity and mortality in women worldwide (1). As the use of screening mammography grows, the proportion of invasive breast cancer with tumor size 1 cm is increasing. It is reported that these patients had a favorable prognosis with complete surgical resection of primary tumor, even without systemic adjuvant therapy, and many international multicenter clinical trials also excluded them (2,3). However, according to the data of SEER , 10-year mortality of these patients was 4% (4). If they were not treated with adjuvant chemotherapy, 10 30% (5) of the cases eventually recurred. The 2007 St Gallen criteria divided breast cancer patients into low-, intermediate- and high-risk groups. Tumors with # The Author Published by Oxford University Press. All rights reserved. For Permissions, please journals.permissions@oup.com

2 472 T1mic, a, bn0m0 breast cancer node-negative, size 2 cm, G1, no peritumoral vascular invasion, human epidermal growth factor receptor 2 (HER2)-negative and age 35 years could be low-risk diseases. So, there were several clinical and pathological factors which might play a prognostic role within the group of patients with small tumors and node-negative disease. In this study, we retrospectively investigated the general features, clinicopathological features, treatments and outcomes obtained in 372 T1mic, a, bn0m0 patients followed at our hospital with the diagnosis of breast cancer between 2002 and PATIENTS AND METHODS We collected the information on 4487 cases operated on from January 2002 to December 2005 at Cancer Institute and Hospital of Tianjin Medical University, and 372 T1mic, a, bn0m0 cases were enrolled. Tumor stage was based on the 6th American Joint Committee on Cancer (AJCC) criteria. Histological type and grading followed the World Health Organization (WHO) classification. The following pathologic information was obtained: tumor size and histological subtype. Immunohistochemical data were also collected for standard prognostic biomarkers [estrogen receptor (ER), progesterone receptor (PR), HER2]. The threshold for ER and PR positivity was 10%. For HER2 assessment, tumors were scored according to the intensity and completeness of cell membrane staining, in a four-tier scale (0: no immunoreactivity, 1þ: weak and incomplete membrane staining or,10% weak but complete membrane staining, 2þ: 10% weak/moderate and complete membrane staining or 30% strong and complete membrane staining, 3þ: 30% strong and complete membrane staining). Tumors scored 3þ were considered as overexpressing HER2. The immunohistochemical classification was as follows: Luminal A (ERþ or PRþ) and (HER2 0/þ/þþ); Luminal B (ERþ or PRþ) and (HER2 þþþ); HER2-positive: (ER2 and PR2) and(her2þþþ); and triple-negative (ER2 and PR2) and(her20/þ/þþ). The Mantel Haenszel x 2 test for trend was used to assess the association between, respectively, categorical and ordinal variables. The endpoints were the incidence of disease-free survival (DFS). DFS was defined as the time from randomization to the first of any of the following events: recurrence of the disease at a local, regional or distant site; a new invasive cancer in the contralateral breast; any second (non-breast) cancer; or death without a previous cancer event. Univariate analysis and survival plots of different subtype were drawn using the Kaplan Meier method. The log-rank test was used to assess survival difference between strata. The Cox regression was applied for multivariate prognostic analysis. Statistical significance was considered at P, All analyses were carried out with the SPSS16.0 software. RESULTS In 372 (8.3%) eligible cases, 63 (16.9%) patients were classified as T1mic, 121 (32.5%) as T1a and 188 (50.5%) as T1b. The median follow-up was months (range: months). Table 1 shows the baseline characteristics of Table 1. Comparison of clinical features between T1mic, a, bn0m0 and other breast cancers [n (%)] Characteristics Stage x 2 P value T1mic, a, bn0m0 (n ¼ 372) Others (n ¼ 4115) Age (years),35 14 (3.8%) 206 (5.0%) (96.2%) 3909 (95.0%) Tumor grade G1 47 (12.6%) 156 (3.8%) ** G2 250 (67.2%) 3167 (77.0%) G3 12 (3.2%) 570 (13.9%) unknown 63 (16.9%) 222 (5.4%) ER Positive 234 (62.9%) 2364 (57.4%) * Negative 138 (37.1%) 1751 (42.6%) PR Positive 202 (54.3%) 2276 (55.3%) Negative 170 (45.7%) 1839 (44.7%) HR ERþ and/or PRþ 254 (68.3%) 2579 (62.7%) * ER2PR2 118 (31.7%) 1536 (37.3%) HER2 Positive 111 (29.8%) 1119 (27.2%) Negative 261 (70.2%) 2996 (72.8%) Surgery Mastectomy 334 (89.8%) 3851 (93.6%) ** Breast-conserving surgery 38 (10.2%) 264 (6.4%) Adjuvant chemotherapy Yes 330 (88.7%) 3934 (95.6%) ** No 42 (11.3%) 181 (4.4%) Adjuvant radiotherapy Yes 36 (9.7%) 2789 (67.8%) ** No 336 (90.3%) 1326 (32.2%) Adjuvant endocrine therapy Yes 240 (64.5%) 2513 (61.1%) No 132 (35.5%) 1602 (38.9%) ER, estrogen receptor; PR, progesterone receptor; HR, hormonal receptor; HER2, human epidermal growth factor receptor 2. *P, **P, 0.01.

3 Jpn J Clin Oncol 2012;42(6) 473 T1mic, a, bn0m0 and other breast cancers. We could conclude that the T1mic, a, bn0m0 group always presented a lower grade, but higher ER and hormonal receptor (HR)-positive rate (all P, 0.05), and these patients tended to undergo more breast-conserving surgery (BCS), less Table 2. Monofactorial analysis of prognosis with early-stage breast cancer Total number Number of evens Five-year disease-free survival rate x 2 P value Tumor size T1mic T1a T1b Age (years), ** Tumor grade G G G Surgery Mastectomy BCS ER Positive Negative PR Positive Negative HR ER2PR ** ERþ and/or PRþ HER2 Positive ** Negative Adjuvant chemotherapy Yes No Adjuvant radiotherapy Yes No Adjuvant endocrine therapy Yes ** No **P, adjuvant chemotherapy and radiotherapy. We also analyzed differences in the characteristics among T1mic, T1a and T1b tumors, and got a conclusion that larger size tumors always accompanied a higher grade, lower ER and HR expression, and higher rate of chemotherapy (data not shown). In these 372 cases, 14 HR-positive patients did not receive adjuvant endocrine therapy, and extra 5 cases did not receive adjuvant radiotherapy after breast conservation surgery. Table 2 shows the univariate analysis results. Young age (,35 years), HR, HER2 and endocrine therapy were risk factors of recurrence. The 5-year cumulative DFS rate for all patients was 94.6%, and the overall survival rate was 98.1%. During the follow-up period, three patients died, one belonged to T1bN0M0 and the other two were T1aN0M0. In addition, breast cancer recurred in 20 patients. Among them, three cases were,35 years, 11 cases with HR-negative, 13 cases with HER2-positive and 11 cases developed systemic recurrence. Table 3 shows the multivariate analysis results. The Cox proportional hazard regression model was constructed using the variables of age, tumor size, grade, adjuvant chemotherapy, adjuvant radiotherapy, HR and HER2 status. The independent prognostic factors of recurrence were HR and HER2 status. The Kaplan Meier estimated that the percentage of patients who remained disease free at 5 years was 98.9% of the Luminal A group, 92.9% of the Luminal B group, 95.0% of the triple-negative group and 86.3% of the HER2-positive group (Fig. 1). Patients of the Luminal A group had a better prognosis than other three groups, and statistical significance was achieved, especially when Luminal A subtype was compared with HER2-positive subtype. However, no statistical significance was achieved among the other three subtypes (Table 4). We also made a further analysis of 5-year recurrence risk (data not shown). Overall, in the HR-positive group, the hazard ratio (HR) associated with HER2 overexpression was [95% confidence interval (CI), ]. In contrast, it was (95% CI, ) in the HR-negative group. Table 3. Multivariate Cox s regression prognostic analysis of all breast cancer in 5-year DFS P value HR 95% CI for HR Age (,35 years) Tumor size Grade HR HER Adjuvant chemotherapy Adjuvant radiotherapy DFS, disease-free survival; HR, hazard ratio; CI, confidence interval.

4 474 T1mic, a, bn0m0 breast cancer DISCUSSION Patients with node-negative, tumor size 1 cm belonged to the early stage. The literature showed that even without systemic adjuvant chemotherapy, they could get an excellent prognosis after mastectomy (6). For patients with microinvasive breast cancer, which was defined as tumor foci of 0.1 cm or less, the recurrence risk and mortality were even lower. However, according to the 2007 St Gallen criteria for low-, medium- and high-risk group classification, the evaluation indicators were more than these two factors. Therefore, we summarized the clinical and pathological features of T1mic, a, bn0m0 patients and analyzed the prognosis to provide more references. Our study elucidated that these patients had a favorable prognosis. Among 376 patients, 3 patients died during the follow-up period, 20 patients experienced recurrence of disease and 5-year DFS was 94.6%. Previously to our study, Kwon et al. (7) analyzed 375 Korean women of T1a, bn0m0 breast cancer. One patient died and 12 recurred. In addition, 10-year outcomes in a population-based cohort study (5), including 430 cases, revealed that patients with Figure 1. Comparison of 5-year disease-free survival between the four subtypes. Grade 3 tumor had shorter 10-year recurrence-free survival, and the difference was statistically significant (74 vs. 82%, P ¼ 0.007). Our research indicated that the large tumor size was always associated with a higher grade, and the differences were significant (P ¼ 0.000). Although the difference in 5-year recurrence rate in each grade was not significant (P ¼ 0.959), Grade III patients had a higher recurrence rate than the other two. Univariate analysis illustrated that age,35 years, endocrine therapy, HR and HER2 were prognostic factors. In the meantime, multivariate analysis represented that HR and HER2 status were associated with a shorter 5-year DFS. It was reported that age,35 years breast cancer always had a poor prognosis than older counterparts. Nevertheless, our study did not support that opinion, which may be relevant to a small number of cases. However, the influence of young age could not be ignored, especially for Asian women, facing a higher morbidity than Western countries (8 10). Among 38 (10%) cases who received BCS, 5 cases, belonging to T1mic and T1a, did not accept post-operative radiotherapy. In these 38 cases, only one case developed into systemic recurrence but not local recurrence during the 5-year follow-up. So, the short-term follow-up indicated the importance of the necessity of adjuvant radiotherapy after BCS. Kwon et al. (7) also showed that patients with T1mic disease had a higher proportion of HER2-positive disease but a very low potential of systemic metastasis of recurrence. In our study, HER2 expression rates in T1mic, T1a and T1b were 34.9, 28.1 and 29.3% (P ¼ 0.600), respectively. The trend was similar to other literatures, but it was still unclear why T1mic accompanied a higher HER2 expression. Multivariate analysis exhibited that HR and HER2 were independent prognosis factors. So, we made a further analysis by dividing all tumors into four intrinsic subtypes. Patients of the Luminal A group had a better prognosis than other three groups, and statistical significance was achieved in comparison, especially when the Luminal A subtype was compared with the HER2-positive subtype. However, no statistical significance was achieved among the other three subtypes. With the Cox regression analysis, we found that in the HR-positive group, HER2-positive (Luminal B) patients had a four times higher recurrence risk than HER2-negative Table 4. Comparison of 5-year DFS among the four subtypes Immunohistochemical classification Luminal A Luminal B Triple-negative HER2-positive x 2 P value x 2 P value x 2 P value x 2 P value Luminal A Luminal B Triple-negative HER2-positive

5 Jpn J Clin Oncol 2012;42(6) 475 (Luminal A) patients (hazard ratio ¼ 4.995; 95% CI ). However, there was no difference in HR-negative groups (hazard ratio ¼ 2.791; 95% CI ). In recent years, many researches joined in the discussion about whether HER2 overexpression was an independent factor of recurrence for early breast cancer. In the 2008 St Antonio conference, experts had referred that HER2 overexpression was a poor prognostic factor. One study (11) investigated patients with node-negative and pt1a-b breast cancer, and results showed that in patients with HR-positive disease, HER2 overexpression was associated with a worse DFS (hazard ratio ¼ 5.1, 95% CI ), but no difference was found in HR-negative disease. A retrospective cohort study to assess the value of 10 prognostic factors in pt1n0m0 patients (12) analyzed 852 T1N0M0 cases, 313 cases with tumor size,1 cm. HER2-positive diseases had a higher recurrence risk than HER2-negative disease (hazard ratio ¼ 2.56; 95% CI ; P ¼ 0.04). Another study about HER2-positive patients (13) summarized the data of 965 pt1a, bn0m0 cases, and the results were that the 5-year DFS rate was 77.1% for HER2-positive disease and 93.7% for HER2-negative disease. The difference was statistically significant (P, 0.001). Now several randomized, controlled trials (RCTs) (2,4) have demonstrated significant improvements in breast cancer recurrence and death associated with the addition of trastuzumab to chemotherapy in the adjuvant setting. All these trials excluded patients with tumors 1 cm in diameter. However, there was no hint from any of the RCTs that the efficacy of trastuzumab, endocrine therapy or chemotherapy would depend on the tumor size (14,15). Therefore, they are expected to benefit from these therapies. The National Comprehensive Cancer Network considered trastuzumab as an option for HER2-positive tumors between 0.6 and 1 cm. However, the cardiotoxicity of trastuzumab was idiosyncratic, was unrelated to dose, displayed a wide range of severity and was reversible in most cases but not all cases (16), and the long-term safety data were still absent (17 19). So whether to add trastuzumab must be balanced with all these things. Our study also had some limitations. First, there were no immunohistochemical results of ER, PR and HER2 for a little portion of patients. Some patients could not be contacted and their survival status could not be included in the analysis. As a result, datum cannot be 100% complete. Secondly, ER- and PR-positive were defined as 10% in our study, but in recent studies if 1% or more of tumor nuclei were stained, they were classified as HR-positive. So, there may be a possibility that tumors with positive staining of ER and PR between 1 and 9% may be defined as HR-negative. Thirdly, some cases only had a short-term follow-up. If it could be prolonged, we could further analyze the relations between the recurrence rate and time. In conclusion, breast cancer with T1mic, a, bn0m0 always had favorable prognosis. HR and HER2 status were independent factors for these patients. Especially in HR-positive groups, the HER2-positive disease recurrence rate was higher than HER2-negative disease. These findings suggested that these patients may benefit from anti-her2 therapy. From the epidemiological standpoint, small tumors are an emerging problem mainly due to screening programs. More International multicenter clinical trials should be carried out so that concrete, effective and personalized treatments could be formulated for these patients. Acknowledgements The authors are grateful to all the staff at the study centers who contribute to this study. Conflict of interest statement None declared. References 1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality Int J Epidemiol 2005;34: Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354: Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25: Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004;22: Joensuu H, Pylkkänen L, Toikkanen S. Late mortality from pt1n0m0 breast carcinoma. Cancer 1999;85: Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 2010;10: Winchester DP. Breast cancer in young women. Surg Clin North Am 1996;76: Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77: Han W, Kim SW, Park IA, et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 2004;4: Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27: Joensuu H, Isola J, Lundin M, et al. Amplification of erbb2 and erbb2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pt1n0m0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9: Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27: Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:

6 476 T1mic, a, bn0m0 breast cancer 15. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19: Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005;23: Hayes DF, Picard MH. Heart of darkness: the downside of trastuzumab. J Clin Oncol 2006;24: Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010;102: Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:

SCIENCE CHINA Life Sciences

SCIENCE CHINA Life Sciences SCIENCE CHINA Life Sciences RESEARCH PAPER April 2013 Vol.56 No.4: 335 340 doi: 10.1007/s11427-013-4435-y Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective

More information

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05

Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05 Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Hormone receptor and Her2 neu (Her2) analysis

Hormone receptor and Her2 neu (Her2) analysis ORIGINAL ARTICLE Impact of Triple Negative Phenotype on Breast Cancer Prognosis Henry G. Kaplan, MD* and Judith A. Malmgren, PhD à *Swedish Cancer Institute at Swedish Medical Center; HealthStat Consulting

More information

A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer

A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer A Review of the Management of T1a/bN0 HER2-Overexpressed Breast Cancer Kelly Khai Li Yap, MD, Debu Tripathy, MD Abstract Small node negative breast cancers measuring less than 1 cm (pt1a/bn0) are generally

More information

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. Cancello, P. Maisonneuve, N. Rotmensz, G. Viale, M. G. Mastropasqua, G.

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva

Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer

More information

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience

Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C, Heidel RE, Desai P, McLoughlin J, Panella T, Bell

More information

Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)?

Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Are there the specific prognostic factors for triplenegative subtype of early breast cancers (pt1-2n0m0)? Department of General Surgery, Anam Hospital, Korea University, College of Medicine, 126-, Anam-dong

More information

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer

Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast Cancer DOI:10.22034/APJCP.2017.18.4.1151 Trastuzumab RESEARCH ARTICLE Outcomes of Trastuzumab Therapy for 6 and 12 Months in Indonesian National Health Insurance System Clients with Operable HER2-Positive Breast

More information

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer

Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Prognostic significance of stroma tumorinfiltrating lymphocytes according to molecular subtypes of breast cancer Hee Jung Kwon, Nuri Jang, Min Hui Park, Young Kyung Bae Department of Pathology, Yeungnam

More information

The effect of delayed adjuvant chemotherapy on relapse of triplenegative

The effect of delayed adjuvant chemotherapy on relapse of triplenegative Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,

More information

Cover Page. The handle holds various files of this Leiden University dissertation

Cover Page. The handle   holds various files of this Leiden University dissertation Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional

More information

Would 1.0 cm be a more suitable cutoff to subdivide pt1 tumors in hormone receptor negative and HER2 positive breast cancer?

Would 1.0 cm be a more suitable cutoff to subdivide pt1 tumors in hormone receptor negative and HER2 positive breast cancer? Received: 30 May 2018 Revised: 11 August 2018 DOI: 10.1002/cam4.1785 Accepted: 29 August 2018 ORIGINAL RESEARCH Would 1.0 cm be a more suitable cutoff to subdivide pt1 tumors in hormone receptor negative

More information

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy

Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Case Series Clinical and pathological portraits of axillary presentation breast cancer and effects of preoperative systemic therapy Ling Xu 1*, Fang Li 1,2*, Yinhua Liu 1, Xuening Duan 1, Jingming Ye 1,

More information

Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time

Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving Outcome Over Time Original Article http://dx.doi.org/1.339/ymj.1.55.5.117 pissn: 513-579, eissn: 197-37 Yonsei Med J 55(5):117-1195, 1 Long-Term Survival Analysis of Korean Breast Cancer Patients at a Single Center: Improving

More information

Molecular subtypes in patients with inflammatory breast cancer; A single center experience

Molecular subtypes in patients with inflammatory breast cancer; A single center experience JBUON 05; 0(): 35-3 ISSN: 0-065, online ISSN: 4-63 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Molecular subtypes in patients with inflammatory breast cancer; A single center experience

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Netw Open. 2018;1(4):e181100.

More information

Heather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD

Heather M. Gage, MD, Avanti Rangnekar, Robert E. Heidel, PhD, Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, PhD HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF CLINICAL TRIALS Heather M. Gage, MD, Avanti Rangnekar,

More information

Radiation Therapy for the Oncologist in Breast Cancer

Radiation Therapy for the Oncologist in Breast Cancer REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10

More information

Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients

Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients BIOSCIENCES BIOTECHNOLOGY RESEARCH ASIA, December 2015. Vol. 12(3), 2221-2225 Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients S.M. Hosseini¹, H. Shahbaziyan

More information

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman

More information

The Clinical Significance of. Triple-negative Phenotype on. Cancer Patients

The Clinical Significance of. Triple-negative Phenotype on. Cancer Patients The Clinical Significance of Triple-negative Phenotype on Prognosis of Young Age( 35) Breast Cancer Patients IM-KYUNG KIM Department of Medicine The Graduate School, Yonsei University The Clinical Significance

More information

Treatment of HER-2 positive breast cancer

Treatment of HER-2 positive breast cancer EJC SUPPLEMENTS 6 (2008) 21 25 available at www.sciencedirect.com journal homepage: www.ejconline.com Treatment of HER-2 positive breast cancer Matteo Clavarezza, Marco Venturini * Ospedale Sacro Cuore

More information

CONS. Dr. Janice Tsang MBBS, MRCP(UK), FRCP (Lond.), FRCP (Edin.), FHKCP, FHKAM (Medicine)

CONS. Dr. Janice Tsang MBBS, MRCP(UK), FRCP (Lond.), FRCP (Edin.), FHKCP, FHKAM (Medicine) Role of Trastuzumab in Small HER2+ Early Breast Cancer CONS Dr. Janice Tsang MBBS, MRCP(UK), FRCP (Lond.), FRCP (Edin.), FHKCP, FHKAM (Medicine) Specialist in Medical Oncology Clinical Assistant Professor

More information

IJC International Journal of Cancer

IJC International Journal of Cancer IJC International Journal of Cancer Patterns of recurrence and treatment in male breast cancer: A clue to prognosis? Miguel Henriques Abreu 1, Pedro Henriques Abreu 2,Noemia Afonso 1, Deolinda Pereira

More information

Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes

Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with positive axillary lymph nodes Cancer Biol Med 2014;11:123-129. doi: 10.7497/j.issn.2095-3941.2014.02.007 ORIGINAL ARTICLE Effects of postmastectomy radiotherapy on prognosis in different tumor stages of breast cancer patients with

More information

Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study

Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective

More information

Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology

Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology Ann Surg Oncol DOI./s-7-9-x ORIGINAL ARTICLE BREAST ONCOLOGY Bioscore: A Staging System for Breast Cancer Patients that Reflects the Prognostic Significance of Underlying Tumor Biology Elizabeth A. Mittendorf,

More information

Breast cancer in octogenarian women: clinical characteristics and outcome

Breast cancer in octogenarian women: clinical characteristics and outcome JBUON 2013; 18(2): 328-334 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Breast cancer in octogenarian women: clinical characteristics and outcome T. Y. Kuzan 1, E. Koca 1, O. Dizdar

More information

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University

More information

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China Clinical research Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China Tao Qin 1, Zhong-Yu Yuan 1, Rou-Jun Peng 1, Bing Bai

More information

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer

A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Elmer ress Original Article World J Oncol. 2017;8(3):71-75 A Retrospective Analysis of Clinical Utility of AJCC 8th Edition Cancer Staging System for Breast Cancer Hui Hu a, Wei Wei a, Xin Yi a, Ling Xin

More information

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection

Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts

More information

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center

PMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic

More information

Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?

Is adjuvant chemotherapy necessary for Luminal A-like breast cancer? JBUON 2018; 23(4): 877-882 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Is adjuvant chemotherapy necessary for Luminal A-like breast cancer?

More information

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein

More information

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast

More information

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta

More information

Original Article Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study

Original Article Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study Int J Clin Exp Pathol 2018;11(5):2665-2674 www.ijcep.com /ISSN:1936-2625/IJCEP0072542 Original Article Long term prognosis of ductal carcinoma in situ with microinvasion: a retrospective cohort study Tianjie

More information

Role of Primary Resection for Patients with Oligometastatic Disease

Role of Primary Resection for Patients with Oligometastatic Disease GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital

Breast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant

More information

Oncotype DX testing in node-positive disease

Oncotype DX testing in node-positive disease Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype

More information

Breast cancer presents a major risk to American. Cancer recurrence and survival in patients with early-stage triple-negative breast cancer

Breast cancer presents a major risk to American. Cancer recurrence and survival in patients with early-stage triple-negative breast cancer Original Research Cancer recurrence and survival in patients with early-stage triple-negative breast cancer Neal P. Christiansen, MD, 1 Lei Chen, MD, PhD, 2 James Gilmore, DPharm, 3 and Stephen Szabo,

More information

Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019

Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 RESEARCH ARTICLE Editorial Process: Submission:11/30/2017 Acceptance:01/04/2019 in Non-Metastatic Triple-Negative Breast Cancer O Al jarroudi*, A Zaimi, S A Brahmi, S Afqir Abstract Introduction: Triple-negative

More information

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases

Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Clinical Study on Prognostic Factors and Nursing of Breast Cancer with Brain Metastases Ying Zhou 1#, Kefang Zhong 1#, Fang Zhou* 2 ABSTRACT This paper aims to explore the clinical features and prognostic

More information

Favorable Prognosis in Patients With T1a/T1bN0 Triple-Negative Breast Cancers Treated With Multimodality Therapy

Favorable Prognosis in Patients With T1a/T1bN0 Triple-Negative Breast Cancers Treated With Multimodality Therapy Favorable Prognosis in Patients With T1a/T1bN0 Triple-Negative Breast Cancers Treated With Multimodality Therapy Alice Y. Ho, MD 1 ; Gaorav Gupta, MD, PhD 1 ; Tari A. King, MD 2 ; Carmen A. Perez, MD 1

More information

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015 Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant

More information

METASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER

METASTASES OF PATIENTS WITH EARLY STAGES OF BREAST CANCER Trakia Journal of Sciences, No 4, pp 7-76, 205 Copyright 205 Trakia University Available online at: http://www.uni-sz.bg ISSN 33-7050 (print) doi:0.5547/tjs.205.04.02 ISSN 33-355 (online) Original Contribution

More information

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case

Breast Cancer? Breast cancer is the most common. What s New in. Janet s Case Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of

More information

Annals of Breast Cancer. MedDocs Publishers. Open Access Research Article. Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4 ; Gupta RK 2,3

Annals of Breast Cancer. MedDocs Publishers. Open Access Research Article. Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4 ; Gupta RK 2,3 Long-term outcome data for patients with HER2- positive early-stage breast cancer treated with adjuvant trastuzumab: Benefit outside clinical trial setting Quintyne KI 1,2* ; Woulfe B 3 ; Coffey JC 2,4

More information

RESEARCH COMMUNICATION. High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer

RESEARCH COMMUNICATION. High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer RESEARCH COMMUNICATION High Ki-67 Expression is a Poor Prognostic Indicator of 5-Year Survival in Patients with Invasive Breast Cancer Xue-Qin Yang 1,2, Fu-Bing Wang 1, Chuang Chen 1, Chun-Wei Peng 1,

More information

original articles introduction

original articles introduction Annals of Oncology 19. List HJ, Reiter R, Singh B et al. Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat 2001; 68: 21 28. 20. Jansson A, Delander

More information

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology

Endocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer

More information

Ca in situ e ormonoterapia. Discussant : LORENZA MARINO

Ca in situ e ormonoterapia. Discussant : LORENZA MARINO Ca in situ e ormonoterapia Discussant : LORENZA MARINO Ca in situ e ormonoterapia Quali fattori di rischio? Radioterapia? Ormonoterapia? BCS Recurrence rates (FUP 13-20y) Cuzick, Lancet Oncol.2011; 12(1):

More information

Clinical Study The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis

Clinical Study The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis Hindawi Analytical Cellular Pathology Volume 2017, Article ID 1350618, 5 pages https://doi.org/10.1155/2017/1350618 Clinical Study The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced

More information

Summary BREAST CANCER - Early Stage Breast Cancer... 3

Summary BREAST CANCER - Early Stage Breast Cancer... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 BREAST CANCER - Early Stage Breast Cancer... 3 Large data analysis reveals similar survival outcomes with sequential

More information

Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates

Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the Best Candidates Ann Surg Oncol (2012) 19:3771 3776 DOI 10.1245/s10434-012-2404-5 ORIGINAL ARTICLE BREAST ONCOLOGY Repeating Conservative Surgery after Ipsilateral Breast Tumor Reappearance: Criteria for Selecting the

More information

Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer

Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics

More information

Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up

Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous

More information

Key Words. Breast cancer Pathological complete response Prognosis Clinical stage

Key Words. Breast cancer Pathological complete response Prognosis Clinical stage The Oncologist Breast Cancer Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response SHAHEENAH DAWOOD, a,f KRISTINE BROGLIO, b SHU-WAN KAU, a RABIUL ISLAM, a W.

More information

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

More information

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT

More information

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer

More information

The HERA Study Team. Presented by Ian E. Smith

The HERA Study Team. Presented by Ian E. Smith Trastuzumab Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer (HERA Trial): Disease-Free and Overall Survival after 2 Year Median Follow-Up The HERA Study Team Presented by Ian E. Smith

More information

Breast-Conserving Therapy for Triple-Negative Breast Cancer

Breast-Conserving Therapy for Triple-Negative Breast Cancer Research Original Investigation PACIFIC COAST SURGICAL ASSOCIATION Breast-Conserving Therapy for Triple-Negative Breast Cancer Alexandra Gangi, MD; Alice Chung, MD; James Mirocha, MS; Douglas Z. Liou,

More information

Research Article Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer

Research Article Locoregional and Distant Recurrence Patterns in Young versus Elderly Women Treated for Breast Cancer International Journal of Breast Cancer Volume 2015, Article ID 213123, 9 pages http://dx.doi.org/10.1155/2015/213123 Research Article Locoregional and Distant Recurrence Patterns in Young versus Elderly

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2

More information

Οutcomes for patients who are diagnosed with breast and endometrial cancer

Οutcomes for patients who are diagnosed with breast and endometrial cancer Washington University School of Medicine Digital Commons@Becker Open Access Publications 2013 Οutcomes for patients who are diagnosed with breast and endometrial cancer Tonya M. Martin-Dunlap Washington

More information

Prognostic implications of the intrinsic molecular subtypes in male breast cancer

Prognostic implications of the intrinsic molecular subtypes in male breast cancer JBUON 2017; 22(2): 377-382 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Prognostic implications of the intrinsic molecular subtypes in male

More information

Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer

Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Clinico- Pathological Features And Out Come Of Triple Negative Breast Cancer Dr. HassanAli Al-Khirsani, MBChB, CABM, F.I.C.M.S AL-Sadder teaching hospital, oncology unit Dr. Nasser Ghaly Yousif, MBChB,G.P.

More information

Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients

Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients 1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of

More information

J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION VOLUME 9 NUMBER 5 DECEMBER JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Novel Staging System for Predicting Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention:

More information

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

More information

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting

ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Malaysian J Pathol 2017; 39(2) : 141 148 ORIGINAL ARTICLE The value of Nottingham grade in breast cancer re-visited in the Sri Lankan setting Harshini PEIRIS PhD, Lakmini MUDDUWA MBBS, MD*, Neil THALAGALA

More information

Immunohistochemical classification of breast tumours

Immunohistochemical classification of breast tumours Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,

More information

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 36 DECEMBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer

More information

Non-Anthracycline Adjuvant Therapy: When to Use?

Non-Anthracycline Adjuvant Therapy: When to Use? Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for

More information

Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients

Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Pathological Lymph Node Positive Breast Cancer Patients Original Articles Jpn J Clin Oncol 2012;42(11)995 1001 doi:10.1093/jjco/hys130 Advance Access Publication 21 August 2012 Stage-to-stage Comparison of Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy

More information

Genomic Profiling of Tumors and Loco-Regional Recurrence

Genomic Profiling of Tumors and Loco-Regional Recurrence 1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,

More information

Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study

Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive lymph nodes: a retrospective study Journal of Radiation Research, 2014, 55, 121 128 doi: 10.1093/jrr/rrt084 Advance Access Publication 20 June 2013 Real-world outcomes of postmastectomy radiotherapy in breast cancer patients with 1 3 positive

More information

Immunoconjugates in Both the Adjuvant and Metastatic Setting

Immunoconjugates in Both the Adjuvant and Metastatic Setting Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor

More information

Table S2. Expression of PRMT7 in clinical breast carcinoma samples

Table S2. Expression of PRMT7 in clinical breast carcinoma samples Table S2. Expression of PRMT7 in clinical breast carcinoma samples (All data were obtained from cancer microarray database Oncomine.) Analysis type* Analysis Class(number sampels) 1 2 3 4 Correlation (up/down)#

More information

Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012

Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory

More information

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive

More information

Downloaded from jhs.mazums.ac.ir at 13: on Friday July 27th 2018 [ DOI: /acadpub.jhs ]

Downloaded from jhs.mazums.ac.ir at 13: on Friday July 27th 2018 [ DOI: /acadpub.jhs ] Iranian Journal of Health Sciences 2016; 4(2): 11-18 Original Article http://jhs.mazums.ac.ir Application of Weibull Accelerated Failure Time Model on the Disease-free Survival Rate of Breast Cancer Narges

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Resection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland

Resection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery

More information

Unexpected features of breast cancer subtype

Unexpected features of breast cancer subtype Liu et al. World Journal of Surgical Oncology (2015) 13:249 DOI 10.1186/s12957-015-0665-8 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Unexpected features of breast cancer subtype Ye-huan Liu,

More information

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome

Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(1):133-141 Original Article http://dx.doi.org/10.4143/crt.2014.262 Open Access Impact of Molecular Subtype Conversion of Breast Cancers after

More information

Nadia Harbeck Breast Center University of Cologne, Germany

Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations

More information

William J. Gradishar MD

William J. Gradishar MD Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley

More information

Results of the ACOSOG Z0011 Trial

Results of the ACOSOG Z0011 Trial DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival

More information

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?

The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? 1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program

More information

Updates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study

Updates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R

More information

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment

More information